DBD increased dCK mRNA and protein expression in tumor-bearing mice, which may affect its enzymatic activity and its role as a potential marker of drug sensitivity in the clinical setting, indicating the potential clinical benefits of combination usage of DBD with GEM and other nucleoside analogues for the treatment of NSCLC. The gene discussed is DCK; the disease is neoplasm.